Can ICER Put a Price on Asthma Control?
October 17, 2018
The Institute for Clinical and Economic Review says new medicine for uncontrolled asthma isn’t worth its cost. But its analysis omits key details.
Categorized in: Analysis
Recent Blog Posts
Hidden Co-Pay Programs Blindside Patients
September 16, 2021
The Urgent Need to Address Urology Health
September 14, 2021
New Federal Policy Could Limit Non-Opioid Pain Treatments
September 10, 2021